Merge Healthcare, an imaging and clinical software company, was ranked among Modern Healthcare's fastest growing companies this year. The company specializes in radiology, cardiology, orthopedics, eye care, clinical trials and financial and presurgical management, according to its website.
On Aug. 24, the U.S. Food and Drug Administration sent a warning letter to Merge detailing what the agency called an inadequate response to violations of good manufacturing practice requirements that an FDA investigator observed during an inspection of Merge blood-pressure computer kiosks. In the letter the FDA asked for a response within 15 business days and said it could enforce seizure, injunctions or civil money penalties without prompt corrective action. An official with Merge Healthcare did not respond by deadline to a request for comment.
In June, the company's largest outside investor, Fidelity Investments, reduced its stake to 1% from more than 50% with the sale of more than 5 million shares, Crain's Chicago Business reported.
In August 2011, the company closed on a deal for Ophthalmic Imaging Systems, Sacramento, Calif. The deal was valued at about $30 million when it was announced in June 2011.
Merge said Thursday that it would not comment on its evaluation until it's finished, the company reaches a deal, or disclosure is required or appropriate.